Surprisingly, lower mRNA expression levels of Musashi-2 were significantly related to poorer overall survival (OS), progression-free survival (PFS) and disease-specific survival (DSS) in patients with ccRCC (Figures 1H, S1A, B). The gene discussed is MSI2; the disease is nonpapillary renal cell carcinoma.